

# Atanu Bhattacharjee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5151687/publications.pdf>

Version: 2024-02-01

108  
papers

1,361  
citations

623188

14  
h-index

395343

33  
g-index

110  
all docs

110  
docs citations

110  
times ranked

1779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of key gene signatures for the overall survival of ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 12.	1.3	5
2	Thresholding of prominent biomarkers of breast cancer on overall survival using classification and regression tree. <i>Cancer Biomarkers</i> , 2022, 34, 319-328.	0.8	2
3	Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with <scp>onceâ€œweek</scp> versus <scp>onceâ€œeveryâ€œ3â€œweeks</scp> cisplatin. <i>Cancer Medicine</i> , 2022, 11, 3939-3948.	1.3	2
4	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 95-103.	1.5	24
5	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. <i>Oral Oncology</i> , 2022, 128, 105816.	0.8	2
6	Population-level Outcomes of Early Thyroid Cancers: A Need to Revisit Current Practice. <i>Rambam Maimonides Medical Journal</i> , 2022, 13, e0008.	0.4	1
7	Long-term outcomes of a randomized controlled clinical trial comparing the efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18008-e18008.	0.8	0
8	Checkpoint inhibitor accessibility in 15,000+ Indian patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9012-9012.	0.8	10
9	Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA6003-LBA6003.	0.8	6
10	Phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA6016-LBA6016.	0.8	4
11	Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6073-6073.	0.8	0
12	Joint modeling of longitudinal and time-to-event data on multivariate protein biomarkers. <i>Journal of Computational and Applied Mathematics</i> , 2021, 381, 113016.	1.1	3
13	When COVID-19 will decline in India? Prediction by combination of recovery and case load rate. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 17-20.	0.9	13
14	Bayesian competing risk analysis: An application to nasopharyngeal carcinoma patients data. <i>Computational and Systems Oncology</i> , 2021, 1, e1006.	1.1	0
15	Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1228-1237.	3.0	14
16	Risk prediction by Raman spectroscopy for disease-free survival in oral cancers. <i>Lasers in Medical Science</i> , 2021, 36, 1691-1700.	1.0	1
17	Illustration of missing data handling technique generated from hepatitis C induced hepatocellular carcinoma cohort study. <i>Journal of King Saud University - Science</i> , 2021, 33, 101403.	1.6	3
18	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e9-496.e15.	0.8	8

#	ARTICLE	IF	CITATIONS
19	A weight function method for selection of proteins to predict an outcome using protein expression data. <i>Journal of Computational and Applied Mathematics</i> , 2021, 391, 113465.	1.1	2
20	Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2709-2716.	0.5	1
21	Missing data handling technique in joint modeling context. <i>Biomedical Engineering Advances</i> , 2021, 2, 100012.	2.2	0
22	Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021, 21, 84.	1.3	3
23	Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study. <i>Ecancermedalscience</i> , 2021, 15, 1318.	0.6	1
24	Prognostic Impact of Pattern of Mandibular Involvement in Gingivo-Buccal Complex Squamous Cell Carcinomas: Marrow and Mandibular Canal Staging System. <i>Frontiers in Oncology</i> , 2021, 11, 752018.	1.3	10
25	A competing risk analysis of death patterns in male genitourinary cancer. <i>Cancer Reports</i> , 2020, 3, e1174.	0.6	2
26	Bayesian competing risks analysis without data stratification. <i>Clinical Epidemiology and Global Health</i> , 2020, 8, 265-270.	0.9	3
27	Comparison of the seventh and eighth editions American Joint Committee Cancer classification system in oral cavity squamous cell cancers. <i>International Journal of Cancer</i> , 2020, 146, 3379-3384.	2.3	10
28	Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 124-136.	0.8	295
29	Parametric survival analysis using R: Illustration with lung cancer data. <i>Cancer Reports</i> , 2020, 3, e1210.	0.6	11
30	Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. <i>Oral Oncology</i> , 2020, 100, 104455.	0.8	9
31	In silico molecular modelling, structural dynamics simulation and characterization of antifungal nature of $\beta$ -glucosidase enzyme from <i>Sechium edule</i> . <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 39, 1-9.	2.0	3
32	Classification algorithm for high-dimensional protein markers in time-course data. <i>Statistics in Medicine</i> , 2020, 39, 4201-4217.	0.8	7
33	Disease progression of cancer patients during COVID-19 pandemic: a comprehensive analytical strategy by time-dependent modelling. <i>BMC Medical Research Methodology</i> , 2020, 20, 209.	1.4	8
34	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	2.9	57
35	Identification of key genes and construction of regulatory network for the progression of cervical cancer. <i>Gene Reports</i> , 2020, 21, 100965.	0.4	2
36	Handling missingness value on jointly measured time-course and time-to-event data. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2020, , 1-21.	0.6	1

#	ARTICLE	IF	CITATIONS
37	An impact of reduction in point prevalence of tobacco use on cancer incidence- A challenge for global policy makers. <i>Clinical Epidemiology and Global Health</i> , 2020, 8, 1287-1296.	0.9	3
38	Reverse swing, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. <i>Cancer Medicine</i> , 2020, 9, 4676-4685.	1.3	16
39	Human papillomavirus elevated genetic biomarker signature by statistical algorithm. <i>Journal of Cellular Physiology</i> , 2020, 235, 9922-9932.	2.0	9
40	The results of sequential swallowing assessments after total laryngectomy for laryngeal and hypopharyngeal malignancies. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 3469-3477.	0.8	3
41	Estimation of Treatment Effect with Missing Observations for Three Arms and Three Periods Crossover Clinical Trials. <i>Annals of Data Science</i> , 2020, 7, 447-460.	1.7	0
42	Joint modeling of longitudinal and time-to-event data with missing time-varying covariates in targeted therapy of oncology. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2020, 6, 330-352.	0.3	1
43	Soft tissue deposit in neck dissection specimen carries a poor prognosis in oral cancer: A matched pair analysis. <i>Head and Neck</i> , 2020, 42, 1783-1790.	0.9	7
44	Salvage surgery in head and neck cancer: Does it improve outcomes?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1052-1058.	0.5	25
45	Aprepitant for Cough Suppression in Advanced Lung Cancer. <i>Chest</i> , 2020, 157, 1647-1655.	0.4	15
46	HER2 borderline is a negative prognostic factor for primary malignant breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 225-231.	1.1	12
47	Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1173-1178.	0.9	9
48	Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6506-6506.	0.8	2
49	Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. <i>Oncotarget</i> , 2020, 11, 399-408.	0.8	12
50	Impact of early reduction in paraprotein on survival in transplant ineligible myeloma: Lesson from a tertiary cancer center in rural India. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 88.	0.3	0
51	Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12092-12092.	0.8	0
52	Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18553-e18553.	0.8	1
53	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. <i>South Asian Journal of Cancer</i> , 2020, 09, 23-26.	0.2	1
54	Alcohol and cancer risk: A systematic review and meta-analysis of prospective Indian studies. <i>Indian Journal of Public Health</i> , 2020, 64, 186.	0.3	6

#	ARTICLE	IF	CITATIONS
55	Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3032-3041.	0.8	51
56	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. <i>Cancer</i> , 2019, 125, 3184-3197.	2.0	73
57	Clinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method. <i>Journal of Translational Medicine</i> , 2019, 17, 184.	1.8	16
58	Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. <i>Neuro-Oncology Practice</i> , 2019, 6, 479-483.	1.0	2
59	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. <i>EClinicalMedicine</i> , 2019, 9, 19-25.	3.2	6
60	Time-course data prediction for repeatedly measured gene expression. <i>International Journal of Biomathematics</i> , 2019, 12, 1950033.	1.5	6
61	A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. <i>Neuro-Oncology Practice</i> , 2019, 6, 305-310.	1.0	0
62	A joint longitudinal and survival model for dynamic treatment regimes in Presence of Competing Risk Analysis. <i>Clinical Epidemiology and Global Health</i> , 2019, 7, 337-341.	0.9	3
63	QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17519-e17519.	0.8	0
64	Prostate cancer survival estimates: An application with piecewise hazard function derivation. <i>South Asian Journal of Cancer</i> , 2019, 08, 150-159.	0.2	0
65	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 6297-6307.	0.8	1
66	Human epidermal growth factor receptor 2 borderline mortality in breast cancer patients: Evidence from surveillance, epidemiology, and end results program population-based study. <i>Clinical Epidemiology and Global Health</i> , 2018, 6, 88-93.	0.9	4
67	Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1064-1072.	0.8	229
68	Bayesian state-space modeling in gene expression data analysis: An application with biomarker prediction. <i>Mathematical Biosciences</i> , 2018, 305, 96-101.	0.9	10
69	Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma. <i>International Journal of Biological Markers</i> , 2018, 33, 283-292.	0.7	2
70	Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6000-6000.	0.8	9
71	An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy. <i>Biometrical Letters</i> , 2018, 55, 1-15.	0.4	1
72	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. <i>South Asian Journal of Cancer</i> , 2018, 07, 249-252.	0.2	8

#	ARTICLE	IF	CITATIONS
73	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.1	0
74	Joint modeling of missing and mismeasured measurements for computing radiotherapy margins. Clinical Epidemiology and Global Health, 2017, 5, 124-130.	0.9	1
75	Neoadjuvant chemotherapy in geriatric head and neck cancers. Head and Neck, 2017, 39, 886-892.	0.9	5
76	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open, 2017, 2, e000168.	2.0	48
77	Impact of waiting time for treatment on survival in patients undergoing radiotherapy for head and neck cancer. Journal of Cancer Policy, 2017, 13, 1-4.	0.6	3
78	Bayesian relative survival : An illustration with lung cancer patients data. Journal of Statistics and Management Systems, 2017, 20, 325-336.	0.3	1
79	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. Oral Oncology, 2017, 75, 54-60.	0.8	11
80	Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease. Journal of Biomolecular Structure and Dynamics, 2017, 35, 1729-1742.	2.0	15
81	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. Chemotherapy Research and Practice, 2017, 2017, 1-4.	1.6	1
82	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy. Ecancermedicalscience, 2017, 11, 776.	0.6	2
83	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. Journal of Global Oncology, 2017, 3, 346-359.	0.5	3
84	Determining an Optimum Biological Dose of A Metronomic Chemotherapy. Journal of Data Science, 2017, 15, 77-94.	0.5	4
85	Assay of urinary protein carbonyl content can predict the steroid dependence and resistance in children with idiopathic nephrotic syndrome. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28, 268.	0.4	8
86	A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. South Asian Journal of Cancer, 2017, 06, 011-014.	0.2	11
87	Alternative of clinical end point selection for metronomic studies. IJS Short Reports, 2017, 2, 50.	0.1	1
88	Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
89	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncology, 2016, 63, 10-15.	0.8	16
90	Risk assessment in liver transplantation patients: A shared frailty parametric approach. Clinical Epidemiology and Global Health, 2016, 4, 1-15.	0.9	1

#	ARTICLE	IF	CITATIONS
91	A selection modelling approach to analysing missing data of liver Cirrhosis patients. Biometrical Letters, 2016, 53, 83-103.	0.4	3
92	Assay of urinary protein-bound sialic acid can differentiate steroidsensitive nephrotic syndrome from steroid-resistant cases. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2016, 27, 37.	0.4	5
93	An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. South Asian Journal of Cancer, 2016, 05, 048-051.	0.2	12
94	Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection. Turkiye Klinikleri Journal of Biostatistics, 2016, 8, 103-109.	0.1	2
95	Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors. Journal of Cancer Research and Therapeutics, 2016, 13, 1023-1026.	0.3	1
96	A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 74-78.	0.1	0
97	Impact of thrombosis on standard treatment in solid tumors. Thrombosis Research, 2015, 136, 943-946.	0.8	4
98	Pilot study of single day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India. Psycho-Oncology, 2015, 24, 832-834.	1.0	11
99	Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance. Journal of Global Oncology, 2015, 1, 65-72.	0.5	3
100	A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncology, 2015, 51, 279-286.	0.8	65
101	Survey of the State of Implementation of the American Society of Clinical Oncology/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India. Journal of Oncology Practice, 2015, 11, 365-369.	2.5	5
102	Bayesian Competing Risks Model: An Application to Breast Cancer Clinical Trial with Incomplete Observations. Journal of Statistics and Management Systems, 2015, 18, 381-404.	0.3	7
103	The Cure Rate Modeling: An Application with Bayesian approach in Liver Cirrhosis Patients. Journal of Data Science, 2015, 13, 421-442.	0.5	1
104	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 161-165.	0.1	20
105	Application of Bayesian Approach in Cancer Clinical Trial. World Journal of Oncology, 2014, 5, 109-112.	0.6	13
106	An Application of Bootstrap Regression Method in Age Dependency Structure to the Community. Indian Journal of Public Health Research and Development, 2013, 4, 44.	0.1	0
107	Bayesian Effective Biological Dose Determination in Immunotherapy Response Trial. Annals of Data Science, 0, , 1.	1.7	0
108	Time Series Analysis Using Different Forecast Methods and Case Fatality Rate for Covid-19 Pandemic. Regional Science Policy and Practice, 0, , .	0.8	1